Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have earned a consensus rating of “Buy” from the six analysts that are presently covering the stock. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.40.
Several research analysts have issued reports on the stock. Piper Jaffray Cos. set a $19.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday. Brean Capital reissued a “buy” rating and set a $24.00 price objective (up from $20.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 29th. JMP Securities raised their price objective on shares of Vanda Pharmaceuticals from $18.00 to $22.00 and gave the stock a “market outperform” rating in a research report on Friday, August 26th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective on the stock in a research report on Tuesday, August 2nd. Finally, Jefferies Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Friday, June 10th.
In other news, insider James E. Flynn sold 1,120,461 shares of the firm’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $16.56, for a total value of $18,554,834.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James E. Flynn sold 547,886 shares of the firm’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $15.66, for a total transaction of $8,579,894.76. The disclosure for this sale can be found here. 8.45% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter valued at approximately $102,000. Bank of Montreal Can purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at approximately $132,000. UBS Asset Management Americas Inc. boosted its stake in Vanda Pharmaceuticals by 10.9% in the second quarter. UBS Asset Management Americas Inc. now owns 16,300 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 1,600 shares during the period. Paloma Partners Management Co purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at approximately $192,000. Finally, Jane Street Group LLC purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at approximately $200,000. Institutional investors own 86.06% of the company’s stock.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.36 on Thursday. The stock’s market cap is $708.13 million. The company’s 50-day moving average is $15.08 and its 200 day moving average is $11.36. Vanda Pharmaceuticals has a 52 week low of $6.91 and a 52 week high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.12. Vanda Pharmaceuticals had a negative net margin of 31.85% and a negative return on equity of 22.51%. The company had revenue of $36.02 million for the quarter, compared to the consensus estimate of $36.03 million. During the same period last year, the firm posted ($0.13) EPS. Vanda Pharmaceuticals’s revenue for the quarter was up 30.6% on a year-over-year basis. Analysts forecast that Vanda Pharmaceuticals will post ($0.61) earnings per share for the current fiscal year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.